# A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

> **NCT03105128** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 931 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** placebo for risankizumab
- **DRUG:** risankizumab IV
- **DRUG:** risankizumab SC

## Key facts

- **NCT ID:** NCT03105128
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-10
- **Primary completion:** 2020-11-09
- **Final completion:** 2021-04-14
- **Target enrollment:** 931 (ACTUAL)
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03105128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03105128, "A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03105128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*